折叠还是不折叠：Hsp90 抑制的调节和后果。
To fold or not to fold: modulation and consequences of Hsp90 inhibition.
机构信息
Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, KA 66045-7563, USA.
出版信息
Future Med Chem. 2009 May;1(2):267-83. doi: 10.4155/fmc.09.17.
Abstract
BACKGROUND
The 90-kDa heat-shock proteins (Hsp90) have rapidly evolved into promising therapeutic targets for the treatment of several diseases, including cancer and neurodegenerative diseases. Hsp90 is a molecular chaperone that aids in the conformational maturation of nascent polypeptides, as well as the rematuration of denatured proteins.
DISCUSSION
Many of the Hsp90-dependent client proteins are associated with cellular growth and survival and, consequently, inhibition of Hsp90 represents a promising approach for the treatment of cancer. Conversely, stimulation of heat-shock protein levels has potential therapeutic applications for the treatment of neurodegenerative diseases that result from misfolded and aggregated proteins.
CONCLUSION
Hsp90 modulation exhibits the potential to treat unrelated disease states, from cancer to neurodegenerative diseases, and, thus, to fold or not to fold, becomes a question of great value.
摘要
背景
90 千道尔顿热休克蛋白（Hsp90）已迅速成为治疗多种疾病（包括癌症和神经退行性疾病）的有希望的治疗靶点。Hsp90 是一种分子伴侣，可帮助新生多肽形成正确构象，并使变性蛋白重新复性。
讨论
许多依赖 Hsp90 的客户蛋白与细胞生长和存活有关，因此抑制 Hsp90 代表了治疗癌症的一种很有前途的方法。相反，刺激热休克蛋白水平具有治疗神经退行性疾病的潜在治疗应用，这些疾病是由错误折叠和聚集的蛋白质引起的。
结论
Hsp90 调节具有治疗无关疾病状态的潜力，从癌症到神经退行性疾病，因此，折叠还是不折叠，成为一个非常有价值的问题。
相似文献
1
To fold or not to fold: modulation and consequences of Hsp90 inhibition.折叠还是不折叠：Hsp90 抑制的调节和后果。
Future Med Chem. 2009 May;1(2):267-83. doi: 10.4155/fmc.09.17.
2
Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.热休克蛋白90（Hsp90）抑制剂：将Hsp90蛋白质折叠机制转变为蛋白质降解催化剂的小分子。
Med Res Rev. 2006 May;26(3):310-38. doi: 10.1002/med.20052.
3
The Right Tool for the Job: An Overview of Hsp90 Inhibitors.适用于该工作的正确工具：Hsp90 抑制剂概述。
Adv Exp Med Biol. 2020;1243:135-146. doi: 10.1007/978-3-030-40204-4_9.
4
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.新生霉素及Hsp90 C端核苷酸结合口袋的其他抑制剂。
Curr Med Chem. 2008;15(26):2702-17. doi: 10.2174/092986708786242895.
5
Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone.通过靶向Aha1共伴侣蛋白的小分子对Hsp90依赖性蛋白质折叠的调控
Cell Chem Biol. 2020 Mar 19;27(3):292-305.e6. doi: 10.1016/j.chembiol.2020.01.008. Epub 2020 Feb 3.
6
Selective Inhibition of the Hsp90α Isoform.选择性抑制 HSP90α 同工型。
Angew Chem Int Ed Engl. 2021 May 3;60(19):10547-10551. doi: 10.1002/anie.202015422. Epub 2021 Mar 26.
7
Small molecule inhibitors targeting heat shock protein 90: An updated review.靶向热休克蛋白 90 的小分子抑制剂：最新综述。
Eur J Med Chem. 2024 Sep 5;275:116562. doi: 10.1016/j.ejmech.2024.116562. Epub 2024 Jun 3.
8
Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.Hsp90 调节的替代策略用于癌症和其他疾病的治疗。
Curr Top Med Chem. 2009;9(15):1447-61. doi: 10.2174/156802609789895683.
9
Hsp90: Friends, clients and natural foes.热休克蛋白90：朋友、客户与天然对手。
Biochimie. 2016 Aug;127:227-40. doi: 10.1016/j.biochi.2016.05.018. Epub 2016 Jun 11.
10
Alternative approaches to Hsp90 modulation for the treatment of cancer.用于癌症治疗的Hsp90调节的替代方法。
Future Med Chem. 2014 Sep;6(14):1587-605. doi: 10.4155/fmc.14.89.
引用本文的文献
1
Putative Roles and Therapeutic Potential of the Chaperone System in Amyotrophic Lateral Sclerosis and Multiple Sclerosis.伴侣蛋白系统在肌萎缩侧索硬化症和多发性硬化症中的推测作用和治疗潜力。
Cells. 2024 Jan 24;13(3):217. doi: 10.3390/cells13030217.
2
A silicon-containing aryl/penta-1,4-dien-3-one/amine hybrid exhibits antiproliferative effects on breast cancer cells by targeting the HSP90 C-terminus without inducing heat-shock response.一种含硅芳基/戊-1,4-二烯-3-酮/胺杂化物通过靶向热休克蛋白90（HSP90）的C末端对乳腺癌细胞发挥抗增殖作用，且不会诱导热休克反应。
RSC Med Chem. 2023 Oct 23;14(12):2625-2639. doi: 10.1039/d3md00431g. eCollection 2023 Dec 13.
3
Protection against Aβ-induced neuronal damage by KU-32: PDHK1 inhibition as important target.KU-32对β-淀粉样蛋白诱导的神经元损伤的保护作用：丙酮酸脱氢酶激酶1抑制作为重要靶点。
Front Aging Neurosci. 2023 Nov 14;15:1282855. doi: 10.3389/fnagi.2023.1282855. eCollection 2023.
4
Pharmacologic Targeting of the C-Terminus of Heat Shock Protein 90 Improves Neuromuscular Function in Animal Models of Charcot Marie Tooth X1 Disease.热休克蛋白90 C末端的药物靶向治疗改善夏科-马里-图斯病X1型动物模型的神经肌肉功能。
ACS Pharmacol Transl Sci. 2023 Jan 20;6(2):306-319. doi: 10.1021/acsptsci.2c00223. eCollection 2023 Feb 10.
5
Recent advances toward the development of Hsp90 C-terminal inhibitors.近年来开发 Hsp90 C 端抑制剂的进展。
Bioorg Med Chem Lett. 2023 Jan 15;80:129111. doi: 10.1016/j.bmcl.2022.129111. Epub 2022 Dec 19.
6
Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology.细胞器靶向治疗：实现精准肿瘤学的系统设计全面综述。
Signal Transduct Target Ther. 2022 Nov 19;7(1):379. doi: 10.1038/s41392-022-01243-0.
7
Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches.热休克蛋白 90 在人类疾病中的作用：从分子机制到治疗方法。
Cells. 2022 Mar 12;11(6):976. doi: 10.3390/cells11060976.
8
Neurobiological Opportunities in Diabetic Polyneuropathy.糖尿病性多发性神经病变中的神经生物学机遇
Neurotherapeutics. 2021 Oct;18(4):2303-2323. doi: 10.1007/s13311-021-01138-y. Epub 2021 Dec 21.
9
Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS.热休克蛋白 90 抑制：治疗 ARSACS 的一种有前途的治疗方法。
Int J Mol Sci. 2021 Oct 29;22(21):11722. doi: 10.3390/ijms222111722.
10
Pharmacological Inhibition of the VCP/Proteasome Axis Rescues Photoreceptor Degeneration in RHO Rat Retinal Explants.VCP/蛋白酶体轴的药理学抑制可挽救 RHO 大鼠视网膜外植体中的光感受器变性。
Biomolecules. 2021 Oct 16;11(10):1528. doi: 10.3390/biom11101528.
本文引用的文献
1
Heat shock protein 90 as a drug target: some like it hot.热休克蛋白90作为一种药物靶点：有人喜欢它的热度。
Clin Cancer Res. 2009 Jan 1;15(1):9-14. doi: 10.1158/1078-0432.CCR-08-0132.
2
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.17-烯丙基氨基-17-去甲氧基格尔德霉素用于转移性黑色素瘤患者的II期试验。
Clin Cancer Res. 2008 Dec 15;14(24):8302-7. doi: 10.1158/1078-0432.CCR-08-1002.
3
Protection mechanisms against Abeta42 aggregation.针对β淀粉样蛋白42聚集的保护机制。
Curr Alzheimer Res. 2008 Dec;5(6):548-54. doi: 10.2174/156720508786898460.
4
Discovery and development of heat shock protein 90 inhibitors.热休克蛋白90抑制剂的发现与研发。
Bioorg Med Chem. 2009 Mar 15;17(6):2225-35. doi: 10.1016/j.bmc.2008.10.087. Epub 2008 Nov 6.
5
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.新生霉素及Hsp90 C端核苷酸结合口袋的其他抑制剂。
Curr Med Chem. 2008;15(26):2702-17. doi: 10.2174/092986708786242895.
6
Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37.热休克蛋白90（Hsp90）依赖的蛋白激酶激活受Cdc37伴侣靶向去磷酸化调节。
Mol Cell. 2008 Sep 26;31(6):886-95. doi: 10.1016/j.molcel.2008.07.021.
7
Recent advances in Hsp90 inhibitors as antitumor agents.热休克蛋白90（Hsp90）抑制剂作为抗肿瘤药物的最新进展。
Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. doi: 10.2174/187152008785914824.
8
Targeting Hsp90: small-molecule inhibitors and their clinical development.靶向热休克蛋白90：小分子抑制剂及其临床开发
Curr Opin Pharmacol. 2008 Aug;8(4):370-4. doi: 10.1016/j.coph.2008.06.015. Epub 2008 Jul 31.
9
Role of the cochaperone Tpr2 in Hsp90 chaperoning.辅助伴侣蛋白Tpr2在Hsp90伴侣功能中的作用。
Biochemistry. 2008 Aug 5;47(31):8203-13. doi: 10.1021/bi800770g. Epub 2008 Jul 12.
10
Heat shock protein 90 modulates LRRK2 stability: potential implications for Parkinson's disease treatment.热休克蛋白90调节富含亮氨酸重复激酶2的稳定性：对帕金森病治疗的潜在影响。
J Neurosci. 2008 Jul 2;28(27):6757-9. doi: 10.1523/JNEUROSCI.1870-08.2008.
Zotero 插件